title: The impact of the President's Emergency Plan for AIDS Relief on expansion of HIV care services for adult patients in western Kenya.
abstract: BACKGROUND
  The President's Emergency Plan for AIDS Relief committed $15 billion to addressing HIV in resource-poor settings.
  
  
  OBJECTIVE
  To assess the impact of The President's Emergency Plan for AIDS Relief on the treatment services of an HIV care program.
  
  
  METHODS
  Cohort study utilizing computerized medical records of nonpregnant adults enrolled into the Academic Model for the Prevention and Treatment of HIV/AIDS system, in western Kenya between 27 November 2001 and 24 July 2006.
  
  
  METHODS
  Number of clinics and patients enrolled in Academic Model for the Prevention and Treatment of HIV/AIDS, as well as patient demographics, immunologic, and clinical characteristics during three periods defined by the availability of combination antiretroviral therapy (cART).
  
  
  RESULTS
  Enrollment as of May 2006 was 23,539. Mean monthly enrollment increased from 64 to 815 between periods 1 and 3. The median CD4 cell count at enrollment during period 3 (172 cells/microl) was significantly higher than for period 2 (119 cells/microl; P < 0.001). World Health Organization stage at enrollment differed significantly between periods with 6.7% having stage 4 disease in period 3 compared with 13.8% during period 1 (P < 0.001). Significantly more patients had complete documentation of cART eligibility, during period 3 as compared with the previous periods. Time from enrollment to cART initiation decreased from a median of 64 weeks in period 1 to 12 weeks during period 3 (P < 0.001).
  
  
  CONCLUSIONS
  The President's Emergency Plan for AIDS Relief funding has allowed Academic Model for the Prevention and Treatment of HIV/AIDS to significantly increase the number of individuals receiving HIV care and provided the ability to expand services allowing for identification of patients earlier in their disease process.
authors.affiliation: Division of Infectious Diseases, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana 46202-5124, USA. kwools@iupui.edu
authors.forename: Kara
authors.initials: K
authors.lastname: Wools-Kaloustian
authors.forename: Silvester
authors.initials: S
authors.lastname: Kimaiyo
authors.forename: Beverly
authors.initials: B
authors.lastname: Musick
authors.forename: John
authors.initials: J
authors.lastname: Sidle
authors.forename: Abraham
authors.initials: A
authors.lastname: Siika
authors.forename: Winstone
authors.initials: W
authors.lastname: Nyandiko
authors.forename: Robert
authors.initials: R
authors.lastname: Einterz
authors.forename: William M
authors.initials: WM
authors.lastname: Tierney
authors.forename: Constantin T
authors.initials: CT
authors.lastname: Yiannoutsos
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D023241:Antiretroviral Therapy, Highly Active / Q000706:statistics & numerical data; D018791:CD4 Lymphocyte Count; D003695:Delivery of Health Care / Q000458:organization & administration*; D003906:Developing Countries; D004630:Emergencies; D005260:Female; D015658:HIV Infections / Q000276:immunology / Q000628:therapy*; D006297:Health Services Accessibility; D006801:Humans; D007391:International Cooperation; D007630:Kenya; D008297:Male; D008507:Medically Underserved Area
chemical_list: D019380:Anti-HIV Agents